Trial Profile

A Therapeutic Trial of Bortezomib (Velcade), Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 May 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Dexamethasone; Imatinib; Methotrexate; Vorinostat
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

01 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
04 Jan 2012 Planned number of patients changed from 18 to 33 as reported by ClinicalTrials.gov.
04 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com